Summary
Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company’s major products include Actikerall, indicated for the treatment of hyperkeratotic actinic keratosis; Beteflam, a topical patch used for the treatment of mild to moderate plaque psoriasis; Epuris, an oral retinoid which is indicated for the treatment of severe nodular and inflammatory acne; Vaniqa, a topical cream indicated to reduce the growth of unwanted facial hair in women; and others. Its products under development are intended for the treatment of seborrheic dermatitis, plaque psoriasis, chronic pruritus, rheumatoid arthritis, late stage melanoma, and others. Its pre-clinical compounds are intended for the treatment of melanoma and other cancers. Cipher is headquartered in Mississauga, Ontario, Canada.
Cipher Pharmaceuticals Inc (CPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 12
Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 13
Cipher Pharma Acquires Assets of Melanovus 14
Partnerships 15
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 15
Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 15
Cipher Pharma Enters Into Distribution Agreement With Medical Futures 16
Cipher Pharma Enters Into Distribution Agreement With Vertical Pharma 17
Licensing Agreements 18
Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 18
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 19
Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 20
Ranbaxy Labs Extends Licensing Agreement with Cipher Pharma for Isotretinoin in Brazil 21
BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 21
Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 22
Debt Offering 23
Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 23
Asset Transactions 24
Cipher Pharma Acquires Assets of Melanovus 24
Acquisition 25
Cipher Pharma Acquires Innocutis 25
Cipher Pharmaceuticals Inc - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cipher Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 12
Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 13
Cipher Pharma Acquires Assets of Melanovus 14
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 15
Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 15
Cipher Pharma Enters Into Distribution Agreement With Medical Futures 16
Cipher Pharma Enters Into Distribution Agreement With Vertical Pharma 17
Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 18
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 19
Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 20
Ranbaxy Labs Extends Licensing Agreement with Cipher Pharma for Isotretinoin in Brazil 21
BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 21
Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 22
Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 23
Cipher Pharma Acquires Assets of Melanovus 24
Cipher Pharma Acquires Innocutis 25
Cipher Pharmaceuticals Inc, Key Competitors 27
Cipher Pharmaceuticals Inc, Key Employees 28
Cipher Pharmaceuticals Inc, Other Locations 29
Cipher Pharmaceuticals Inc, Subsidiaries 29
List of Figures
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
